{"title":"Cognitive impairment and associated factors among patients with mood disorders receiving care at public hospitals in Gedeo zone, Southern Ethiopia.","authors":"Biazin Yenealem Mekuriaw, Hibist Wondmu, Marye Asfaw, Chalachew Kassaw, Alemayehu Molla","doi":"10.1007/s00127-025-02932-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cognitive impairment is characterized by difficulty in attention, memory, problem-solving, and decision-making. It is strongly linked to mood disorders and affects work performance, social interactions, medication adherence, and overall quality of life. Despite the high burden of the problem, evidence on its prevalence and contributing factors remains scarce in low- and middle-income countries. This study aimed to determine the prevalence and associated factors of cognitive impairment among individuals with mood disorders.</p><p><strong>Method: </strong>A cross-sectional study was conducted at Gedeo Zone public hospitals. A systematic sampling technique was used to select a total of 422 individuals receiving care for mood disorders. The outcome variable was assessed using the Montreal Cognitive Assessment (MoCA). The data were entered into Epi Data version 4.2 and analyzed using STATA version 17. Bivariable and multivariable logistic regression analyses were performed to identify factors associated with cognitive impairment. The presence of an association was examined with an adjusted odd ratio with a 95% confidence interval and variables with P values less than 0.05 were considered a statistically significant association.</p><p><strong>Result: </strong>The prevalence of cognitive impairment among individuals with bipolar disorders and depressive disorders was 34.5% (95% CI: 32.7-36.9) and 38.7% (95% CI: 36.4-40.8), respectively. Having a longer duration of treatment [AOR = 1.87 (95% CI: 1.57, 2.94)], a duration of illness 10 years and above [AOR = 2.13 (95% CI 1.23, 4.48)], and severe depressive symptoms [AOR = 2.15 (95% CI 1.14, 4.97)] were significantly associated with cognitive impairment among individuals with depressive disorders. Medication non-adherence [AOR = 1.48 (95% CI: 1.34, 2.78)], a long duration of illness [AOR = 1.42 (95% CI: 1.09, 2.48)], and severe manic symptoms [AOR = 2.16 (95% CI: 1.18, 5.28)] were significantly associated with cognitive impairment among participants with bipolar disorders.</p><p><strong>Conclusion: </strong>This study revealed a high prevalence of cognitive impairment in patients with mood disorders. Therefore, early screening and intervention for cognitive impairment in mood disorder patients are essential to deliver holistic care and improve treatment outcomes. Integrating cognitive assessments into routine mental health evaluations can help identify early deficits and enable tailored interventions. Additionally, cognitive remediation strategies such as structured patient education, side-effect management, and medication adjustments should be prioritized to enhance adherence and overall recovery.</p>","PeriodicalId":49510,"journal":{"name":"Social Psychiatry and Psychiatric Epidemiology","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Social Psychiatry and Psychiatric Epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00127-025-02932-1","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cognitive impairment is characterized by difficulty in attention, memory, problem-solving, and decision-making. It is strongly linked to mood disorders and affects work performance, social interactions, medication adherence, and overall quality of life. Despite the high burden of the problem, evidence on its prevalence and contributing factors remains scarce in low- and middle-income countries. This study aimed to determine the prevalence and associated factors of cognitive impairment among individuals with mood disorders.
Method: A cross-sectional study was conducted at Gedeo Zone public hospitals. A systematic sampling technique was used to select a total of 422 individuals receiving care for mood disorders. The outcome variable was assessed using the Montreal Cognitive Assessment (MoCA). The data were entered into Epi Data version 4.2 and analyzed using STATA version 17. Bivariable and multivariable logistic regression analyses were performed to identify factors associated with cognitive impairment. The presence of an association was examined with an adjusted odd ratio with a 95% confidence interval and variables with P values less than 0.05 were considered a statistically significant association.
Result: The prevalence of cognitive impairment among individuals with bipolar disorders and depressive disorders was 34.5% (95% CI: 32.7-36.9) and 38.7% (95% CI: 36.4-40.8), respectively. Having a longer duration of treatment [AOR = 1.87 (95% CI: 1.57, 2.94)], a duration of illness 10 years and above [AOR = 2.13 (95% CI 1.23, 4.48)], and severe depressive symptoms [AOR = 2.15 (95% CI 1.14, 4.97)] were significantly associated with cognitive impairment among individuals with depressive disorders. Medication non-adherence [AOR = 1.48 (95% CI: 1.34, 2.78)], a long duration of illness [AOR = 1.42 (95% CI: 1.09, 2.48)], and severe manic symptoms [AOR = 2.16 (95% CI: 1.18, 5.28)] were significantly associated with cognitive impairment among participants with bipolar disorders.
Conclusion: This study revealed a high prevalence of cognitive impairment in patients with mood disorders. Therefore, early screening and intervention for cognitive impairment in mood disorder patients are essential to deliver holistic care and improve treatment outcomes. Integrating cognitive assessments into routine mental health evaluations can help identify early deficits and enable tailored interventions. Additionally, cognitive remediation strategies such as structured patient education, side-effect management, and medication adjustments should be prioritized to enhance adherence and overall recovery.
期刊介绍:
Social Psychiatry and Psychiatric Epidemiology is intended to provide a medium for the prompt publication of scientific contributions concerned with all aspects of the epidemiology of psychiatric disorders - social, biological and genetic.
In addition, the journal has a particular focus on the effects of social conditions upon behaviour and the relationship between psychiatric disorders and the social environment. Contributions may be of a clinical nature provided they relate to social issues, or they may deal with specialised investigations in the fields of social psychology, sociology, anthropology, epidemiology, health service research, health economies or public mental health. We will publish papers on cross-cultural and trans-cultural themes. We do not publish case studies or small case series. While we will publish studies of reliability and validity of new instruments of interest to our readership, we will not publish articles reporting on the performance of established instruments in translation.
Both original work and review articles may be submitted.